Hyaluronic acid improves tolerability to 7% hypertonic saline solution in bronchiectasis patients

L. Maiz (Madrid, Spain), R. Giron (Madrid, Spain), E. Prats (Madrid, Spain), M. Clemente (Oviedo, Spain), E. Polverino (Barcelona, Spain), S. Caño (Barcelona, Spain), R. Cordovilla (Salamanca, Spain), J. Dorca (Barcelona, Spain), C. PeñAlver (Murcia, Spain), F. Baranda (Vizcaya, Spain), M. Martinez-Garcia (Valencia, Spain)

Source: International Congress 2018 – Pulmonary drug delivery: inhaler use, devices and technologies
Session: Pulmonary drug delivery: inhaler use, devices and technologies
Session type: Thematic Poster
Number: 1016
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
L. Maiz (Madrid, Spain), R. Giron (Madrid, Spain), E. Prats (Madrid, Spain), M. Clemente (Oviedo, Spain), E. Polverino (Barcelona, Spain), S. Caño (Barcelona, Spain), R. Cordovilla (Salamanca, Spain), J. Dorca (Barcelona, Spain), C. PeñAlver (Murcia, Spain), F. Baranda (Vizcaya, Spain), M. Martinez-Garcia (Valencia, Spain). Hyaluronic acid improves tolerability to 7% hypertonic saline solution in bronchiectasis patients. 1016

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: